Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Barry

Showing results (511-520 of 674) with videos related to

Pageof 68
Sort By:
Analytical Chemistry|February 19, 2021
Method to Investigate the Distribution of Water-Soluble Drug-Delivery Systems in Fresh Frozen Tissues Using Imaging Mass CytometryNicole Strittmatter, Richard M England, Alan M Race, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 27, 2023
Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrenceNikita Sushentsev, Gregory Hamm, Jack Richings, et al.
Cancer Discovery|November 8, 2015
MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in MalignancyManish Neupane, Allison P Clark, Serena Landini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2024
Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non-Small Cell Lung Cancer with PIK3CA/PTEN AlterationsUrsula Grazini, Aleksandra Markovets, Lucy Ireland, et al.
JNCI Cancer Spectrum|May 13, 2021
Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance)Jennifer A Ligibel, Luke Huebner, Hope S Rugo, et al.
The Journal of Clinical Investigation|February 18, 2015
WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibitedLuke Boulter, Rachel V Guest, Timothy J Kendall, et al.
Journal for Immunotherapy of Cancer|November 30, 2019
Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discoveryMolly A Taylor, Adina M Hughes, Josephine Walton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2020
Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastasesO Metzger Filho, J P Leone, T Li, et al.
Plos One|February 2, 2026
The association between long-term opioid therapy and composite infection-related dental outcomesAnne C Black, Kirsha S Gordon, James D Dziura, et al.
Molecular Cancer Therapeutics|February 22, 2012
Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancerMickey K Kim, Takuya Osada, William T Barry, et al.
Pageof 68

Showing results (511-520 of 674) with videos related to

Sort By:
Pageof 68
Analytical Chemistry|February 19, 2021
Method to Investigate the Distribution of Water-Soluble Drug-Delivery Systems in Fresh Frozen Tissues Using Imaging Mass CytometryNicole Strittmatter, Richard M England, Alan M Race, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 27, 2023
Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrenceNikita Sushentsev, Gregory Hamm, Jack Richings, et al.
Cancer Discovery|November 8, 2015
MECP2 Is a Frequently Amplified Oncogene with a Novel Epigenetic Mechanism That Mimics the Role of Activated RAS in MalignancyManish Neupane, Allison P Clark, Serena Landini, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 17, 2024
Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non-Small Cell Lung Cancer with PIK3CA/PTEN AlterationsUrsula Grazini, Aleksandra Markovets, Lucy Ireland, et al.
JNCI Cancer Spectrum|May 13, 2021
Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance)Jennifer A Ligibel, Luke Huebner, Hope S Rugo, et al.
The Journal of Clinical Investigation|February 18, 2015
WNT signaling drives cholangiocarcinoma growth and can be pharmacologically inhibitedLuke Boulter, Rachel V Guest, Timothy J Kendall, et al.
Journal for Immunotherapy of Cancer|November 30, 2019
Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discoveryMolly A Taylor, Adina M Hughes, Josephine Walton, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 29, 2020
Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastasesO Metzger Filho, J P Leone, T Li, et al.
Plos One|February 2, 2026
The association between long-term opioid therapy and composite infection-related dental outcomesAnne C Black, Kirsha S Gordon, James D Dziura, et al.
Molecular Cancer Therapeutics|February 22, 2012
Characterization of an oxaliplatin sensitivity predictor in a preclinical murine model of colorectal cancerMickey K Kim, Takuya Osada, William T Barry, et al.
Pageof 68